Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Trend
Mixed MA signals — sideways/transition | Bearish MA stack (20<50<200)
Price Action
Support & Resistance Levels
Volume Analysis
Recent MA Crossovers
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹1,692.7 Cr | ₹1,637.3 Cr | ₹1,710.7 Cr | ₹1,876.3 Cr |
| Net Profit | ₹138.4 Cr | ₹156.9 Cr | ₹154.4 Cr | ₹133 Cr |
| EPS | ₹7.01 | — | ₹7.85 | ₹6.76 |
| Operating Profit | ₹270.1 Cr | ₹285.5 Cr | ₹287.4 Cr | ₹264.9 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 29 Jul 2025 | Dividend - Rs 11 Per Share | DIVIDEND |
| 15 Jul 2024 | Dividend - Rs 11 Per Share | DIVIDEND |
| 28 Jul 2023 | Dividend - Rs 8 Per Share | DIVIDEND |
| 17 Aug 2022 | Interim Dividend - Rs 10 Per Share | INTERIM_DIVIDEND |
| 19 Jul 2021 | Annual General Meeting/Dividend - Rs 14 Per Share | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for APLLTD
View AllAlembic Pharmaceuticals receives USFDA approval for Tretinoin Cream USP, 0.05%
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tretinoin Cream USP, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Retin-A Cream, 0.05%, of Bausch Health US, LLC. Tretinoin cream is indicated for topical application in the treatment of acne vulgaris.
Alembic Pharma gains after receiving USFDA nod for Tretinoin Cream
Alembic Pharmaceuticals rose 1.33% to Rs 744.75 after the company announced that it had received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Tretinoin Cream USP, 0.05%.
Alembic Pharma gains after receiving USFDA nod for Larotrectinib Capsules
Alembic Pharmaceuticals advanced 1.15% to Rs 744.95 after the company announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Larotrectinib Capsules.